Bimatoprost implant reduces need for rescue treatment in investigational study

Patients had an 80% probability of requiring no IOP-lowering treatment for more than 1 year after the third administration of bimatoprost implant 10μg (BimSR, Durysta, AbbVie Inc.), according to a poster study presented at 2020 AAO Virtual.

Baseline IOP >25 mmHg, prior selective laser trabeculoplasty (SLT), male gender, pseudophakic status, and IOP increase or reduction ≤5 mmHg before the third administration were significantly associated with rescue.

For the study, the researchers set out to identify factors associated with need for rescue IOP-lowering treatment after a third bimatoprost implant 10 μg administration (day 1, weeks 16 and 32) in the 20-month phase 3 ARTEMIS studies. They conducted a multivariable Cox regression analysis of time to first use of rescue for open-angle glaucoma and ocular hypertension (OAG/OHT) patients randomized to the bimatoprost implant. Nineteen percent of patients (61/326), required rescue after third implant administration.

The bimatoprost implant 10 μg is approved for single administration. Registration studies are ongoing to potentially allow for implant re-administration. This analysis of predictive factors for long-term IOP lowering in the phase 3 studies is directional, and additional clinical studies are necessary to further understand patient characteristics predictive of a sustained response to a single administration, the researchers concluded.  

Reference
Khouri AS, et al. Predictive factors for long-term IOP-lowering after bimatoprost implant 10-μg administration in phase 3 ARTEMIS studies. Presented at: AAO 2020 Virtual [Session: PO176].